TY - JOUR
T1 - Determination of teicoplanin trough concentration target and appropriate total dose during the first 3 days
T2 - A retrospective study in patients with MRSA infections
AU - Matsumoto, Kazuaki
AU - Kanazawa, Naoko
AU - Ikawa, Kazuro
AU - Fukamizu, Tomohide
AU - Shigemi, Akari
AU - Yaji, Keiko
AU - Shimodozono, Yoshihiro
AU - Morikawa, Norifumi
AU - Takeda, Yasuo
AU - Yamada, Katsushi
N1 - Funding Information:
Acknowledgments Financial support for this study was provided by the Japan Society for the Promotion of Science (17923059).
PY - 2010/6
Y1 - 2010/6
N2 - An initial loading procedure has been recommended to enable teicoplanin to promptly reach an effective serum concentration for the treatment of methicillinresistant Staphylococcus aureus (MRSA). This study aimed to retrospectively evaluate the pharmacokinetics and pharmacodynamics of teicoplanin to determine the therapeutic target for the teicoplanin trough concentration and an appropriate dosing method during the first 3 days. The mean trough concentrations were 13.2 mg/L for patients with eradication of MRSA. Moreover, logistic regression analysis showed that the teicoplanin trough concentration was 13 mg/L to achieve MRSA eradication with a probability of 89.0%. The rates of achieving ≥13 mg/L in ≤24, 24-36 and ≥36 mg/kg (total dose during the first 3 days) groups were 9.1, 48.4 and 87.5%, respectively. These results suggest that the administration of ≥36 mg/kg during the first 3 days is appropriate to promptly obtain a trough concentration target of ≥13 mg/L for the initial treatment of MRSA infections.
AB - An initial loading procedure has been recommended to enable teicoplanin to promptly reach an effective serum concentration for the treatment of methicillinresistant Staphylococcus aureus (MRSA). This study aimed to retrospectively evaluate the pharmacokinetics and pharmacodynamics of teicoplanin to determine the therapeutic target for the teicoplanin trough concentration and an appropriate dosing method during the first 3 days. The mean trough concentrations were 13.2 mg/L for patients with eradication of MRSA. Moreover, logistic regression analysis showed that the teicoplanin trough concentration was 13 mg/L to achieve MRSA eradication with a probability of 89.0%. The rates of achieving ≥13 mg/L in ≤24, 24-36 and ≥36 mg/kg (total dose during the first 3 days) groups were 9.1, 48.4 and 87.5%, respectively. These results suggest that the administration of ≥36 mg/kg during the first 3 days is appropriate to promptly obtain a trough concentration target of ≥13 mg/L for the initial treatment of MRSA infections.
KW - Methicillin-resistant Staphylococcus aureus (MRSA)
KW - Teicoplanin
KW - Therapeutic drug monitoring
UR - http://www.scopus.com/inward/record.url?scp=77955708826&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=77955708826&partnerID=8YFLogxK
U2 - 10.1007/s10156-010-0038-8
DO - 10.1007/s10156-010-0038-8
M3 - Article
C2 - 20195882
AN - SCOPUS:77955708826
SN - 1341-321X
VL - 16
SP - 193
EP - 199
JO - Journal of Infection and Chemotherapy
JF - Journal of Infection and Chemotherapy
IS - 3
ER -
